how much cbd oil for dog with epilepsy

Investigating Dietary Supplements for the Treatment of Canine Idiopathic Epilepsy

Canine idiopathic epilepsy, defined as recurrent seizures with no identifiable underlying cause, is the most common medical neurologic disease in dogs. Twenty to thirty percent of affected dogs continue to experience seizures despite treatment with currently available anti-epileptic drugs (AEDs). In addition, side effects from these drugs, such as increased appetite, sedation, restlessness, or anxiety, often decrease quality of life for affected dogs and their owners. For these reasons and more, the AKC Canine Health Foundation (CHF) launched its Epilepsy Research Initiative in January 2017 to focus efforts on this devastating condition and improve the understanding of and treatment for epilepsy in dogs.

As part of the Epilepsy Research Initiative, investigators at the Royal Veterinary College, University of London were awarded CHF Grant 02252: Investigating a Ketogenic Medium-Chain Triglyceride (MCT) Supplement for the Treatment of Drug-Resistant Canine Idiopathic Epilepsy and Its Behavioral Comorbidities. They set out to determine whether supplementation with MCT oil altered the side effects of AEDs, improved the behavioral problems associated with epilepsy, or improved the stress level of epileptic dogs. One aspect of this research was to understand owner use of dietary supplements in dogs with idiopathic epilepsy. Owners completed an online questionnaire about their use of dietary supplements and/or diet change in their epileptic dog.

Results of this research were presented at the 2017 Annual European College of Veterinary Neurology/European Society of Veterinary Neurology Conference and the 2017 AKC CHF National Parent Club Canine Health Conference, as well as published in the peer-reviewed journal Research in Veterinary Science in 2018. Investigators found that two-thirds of owners changed their dog’s diet after being diagnosed with epilepsy, but less than 30% of those did so based on the advice of a veterinarian. Almost half of the owners reported giving dietary supplements to manage their dog’s idiopathic epilepsy. The most common supplements given were coconut oil, fish oil, and milk thistle. Other supplements given included cannabidiol (CBD oil), vitamin B12, homeopathic remedies, glucosamine/chondroitin, taurine, and herbs. Only 17.5% of owners consulted their veterinarian on the use of these supplements, while most owners received guidance from owner support groups or online.

All bark, no bite: Some CBD pet products contain 'virtually no CBD'

Companies have unleashed hundreds of CBD pet health products accompanied by glowing customer testimonials claiming the cannabis derivative produced calmer, quieter and pain-free dogs and cats.

But some of these products are all bark and no bite.

“You’d be astounded by the analysis we’ve seen of products on the shelf with virtually no CBD in them,” said Cornell University veterinary researcher Joseph Wakshlag, who studies therapeutic uses for the compound. “Or products with 2 milligrams per milliliter, when an effective concentration would be between 25 and 75 milligrams per milliliter. There are plenty of folks looking to make a dollar rather than produce anything that’s really beneficial.”

FDA holds first public hearing on CBD

Such products can make it to the shelves because the federal government has yet to establish standards for CBD that will help people know whether it works for their pets and how much to give.

Still, there’s lots of individual success stories that help fuel a $400 million market that grew more than tenfold since last year and is expected to reach $1.7 billion by 2023, according to the cannabis research firm Brightfield Group.

Amy Carter of St. Francis, Wisconsin, decided to go against her veterinarian’s advice and try CBD oil recommended by a friend to treat Bentley, her epileptic Yorkshire terrier-Chihuahua mix. The little dog’s cluster seizures had become more frequent and frightening despite expensive medications.

“It’s amazing,” Carter said. “Bentley was having multiple seizures a week. To have only six in the past seven months is absolutely incredible.”


Health U.S. to spend $3 million to find out if CBD can relieve pain

But some pet owners have found CBD didn’t work.

Dawn Thiele, an accountant in Oak Creek, Wisconsin, said she bought a $53 bottle of CBD oil from a local shop in hopes of calming her 2-year-old Yorkshire terrier during long car trips.

“I didn’t see a change in his behavior,” said Thiele, who nonetheless remains a believer.

“The product is good, it just didn’t work for my dog,” she said.

Short for cannabidiol, CBD is a non-intoxicating molecule found in hemp and marijuana. Both are cannabis plants, but only marijuana has enough of the compound THC to get users high. The vast majority of CBD products come from hemp, which has less than 0.3 percent THC.

CBD has garnered a devoted following among people who swear by it for everything from stress reduction to better sleep. Passage of the 2018 Farm Bill, which eased federal legal restrictions on hemp cultivation and transport, unleashed a stampede of companies rushing products to the market in an absence of regulations ensuring safety, quality and effectiveness.

Products for people were swiftly followed by CBD chewies, oils and sprays for pets.

“The growth is more rapid than I’ve seen for any product in 20 years in this business,” said Bill Bookout, president of the National Animal Supplement Council, an industry group whose member companies agree to testing and data-gathering requirements. “There’s a gold rush going on now. Probably 95 percent of the industry participants are responsible, but what’s dangerous is the fly-by-night operative that wants to cash in.”

The U.S. Food and Drug Administration is developing regulations for marketing CBD products, for pets or people. This year, it has sent warning letters to 22 companies citing violations such as making claims about therapeutic uses and treatment of disease in humans or animals or marketing CBD as a dietary supplement or food ingredient.


Health FDA, FTC send warning letters to three CBD marketers for false claims

“It’s really the Wild West out there,” said S. David Moche, founder of Applied Basic Science, a company formed to support Colorado State University’s veterinary CBD research and now selling CBD online. He advises consumers to look for a certificate of analysis from a third-party testing laboratory to ensure they’re getting what they pay for.

“Testing and labeling is going to be a critical part of the future of this industry,” Moche said.

Wakshlag said products must be tested not only for CBD level, but also to ensure they’re free of toxic contaminants such as heavy metals and pesticides and have only trace amounts of THC, which in higher levels is toxic to dogs.

Bookout said his organization has recorded very few health incidents involving CBD and no deaths.

Still, scientific documentation of CBD’s safety and efficacy is nearly nonexistent.

That’s starting to change, however. A small clinical trial at Colorado State University published in the Journal of the American Veterinary Medical Association in June found CBD oil reduced seizure frequency in 89 percent of the epileptic dogs that received it.

A clinical study headed by Wakshlag at Cornell, published in Frontiers in Veterinary Science in July 2018, found CBD oil helped increase comfort and activity in dogs with osteoarthritis.

Stephanie McGrath, a Colorado State University researcher, is now doing a larger clinical trial funded by the American Kennel Club’s Canine Health Foundation.

“The results of our first epilepsy study were promising, but there was certainly not enough data to say CBD is the new miracle anti-convulsive drug in dogs,” McGrath said.

Seizures are a natural focus for research on veterinary CBD products, since Epidiolex, the only FDA-approved drug containing cannabidiol, was approved last year for treatment of two severe forms of epilepsy in children. Veterinarians are allowed to prescribe Epidiolex for pets, but it’s prohibitively expensive — upwards of $30,000 a year for an average-size dog, McGrath said.

The Kennel Club’s chief veterinary officer, Jerry Klein, said CBD is “over-hyped” but promising for treatments like pain relief. He’s hopeful that the growing market will result in more money being invested in research to prove uses.

Meantime, the American Veterinary Medical Association is telling veterinarians they can share what they know about CBD with clients but shouldn’t prescribe or recommend it until the FDA gives its blessing.

“There’s no question there’s veterinary interest in these products as therapies, but we really want to see the manufacturers demonstrate that they’re effective and safe and get FDA approval so we can have confidence in the products,” said Gail Golab, chief veterinary officer for the association.

The RVC calls for vets to participate in survey to help shape the future of epilepsy research

The Canine Epilepsy Research team at the Royal Veterinary College (RVC) is calling for general practice vets to participate in a vital survey being conducted on canine epilepsy therapies and their impact, in order to best support dogs with epilepsy, their owners, and veterinary professionals managing these cases.

The survey, which is being carried out throughout June, was also conducted back in 2016 and is now being repeated in a bid to determine any key developments and outcomes that have been made over the past four years, a time in which several new epilepsy management options have emerged.

The survey asks respondents to firstly prioritise how important they feel different areas of epilepsy research are, then assess how much they think certain new therapies have the potential to positively impact epileptic dogs’ lives. This includes emerging therapies like MCT oil, cannabidiol oil, vagus nerve stimulation and transcranial magnetic stimulation, for which studies are currently being conducted across the globe.

The ultimate aim of the survey is to identify the top priorities for future research for owners, vets and neurologists alike, and also to compare these key groups to see if there are any interesting differences between their priorities and ambitions in this crucial area.

The RVC has been at the forefront of research of canine epilepsy for several years, driving international consensus on the diagnosis and treatment of this common neurological condition. In 2015, the RVC launched the ground-breaking Pet Epilepsy Tracker app which lets owners map seizure activity and medication requirements on their mobile phone or tablet device, and electronically share this vital information with both their own vets and RVC for future research.

Dr Rowena Packer, BBSRC Research Fellow and research lead in canine epilepsy at the RVC, said: “This survey was inspired by similar prioritisation activities undertaken by the International League Against Epilepsy (ILAE) for human epilepsy patients. At the RVC, we believe that the benefits of such an open approach can be truly valuable for veterinary medicine too, and ensure a diversity of views influence future epilepsy priorities.”

Dr Gareth Jones, Small Animal Intern at the RVC who is running the study, said: “While many have already undertaken the survey, we are keen to hear from more participants so I would like to implore any general practice vets to please help contribute to our work by taking part in our short survey.”